1	Relationship	between	Polyunsaturated Fa <sup>.</sup>	tty Acids and Inflam	mation:
---	--------------	---------	---------------------------------	----------------------	---------

- 2 evidence from cohort and Mendelian randomization analyses
- 3 Daisy C. P. Crick <sup>1,2\*</sup>, Sarah Halligan <sup>3,4</sup>, George Davey Smith <sup>1,2</sup>, Golam M. Khandaker <sup>1,2,5,6,7\*</sup>
- 4 & Hannah J. Jones <sup>1,2,5,7\*</sup>

5

16

19

21

- 6 1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
- 7 University of Bristol, Bristol, UK
- 8 2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 9 3. Department of Psychology, University of Bath, Bath, UK
- 4. Department of Psychiatry and Mental Health, University of Cape Town, South Africa
- 5. NIHR Bristol Biomedical Research Centre, Bristol, UK
- 12 6. Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK
- 7. Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
- 14 University of Bristol, Bristol, UK
- 15 \*Joint senior authors
- 17 Author for correspondence: Daisy Crick, University of Queensland, Institute of Molecular
- 18 Bioscience. Email:uqdcrick@uq.edu.au
- 20 Word Count: Abstract: 190/200, Main body 3752/5000

Email: uqdcrick@uq.edu.au

<sup>\*</sup> Author for correspondence: Daisy Crick, University of Queensland, Institute of Medical Bioscience, St Lucia, 4072. Australia.

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39 40

41

42

43

44

45

46

47

Dietary polyunsaturated fatty acids (PUFAs) are thought to influence the risk of various chronic diseases by modulating systemic inflammation. Omega-3 and omega-6 FAs are thought to have anti- and pro-inflammatory roles, respectively, but it is unclear whether these associations are causal. We tested associations of PUFAs with three blood-based biomarkers of systemic inflammation, namely C-reactive protein (CRP), glycoprotein acetyls (GlycA) and interleukin 6 (IL-6), in a population cohort (n=2748) and using Mendelian randomization analysis (a genetic causal inference method). We provide consistent evidence that omega-6 PUFAs increase GlycA levels, but omega-3 FAs do not lower levels of inflammatory markers. Additionally, we found that a higher omega-6:omega-3 ratio increases levels of all three inflammatory markers; CRP (mean difference=0.17; 95% CI=0.13, 0.20), GlycA (mean difference=0.16; 95% CI=0.13, 0.20) and IL-6 (mean differene=0.19; 95% CI=0.15, 0.22) in the cohort analysis. Our findings suggest that future public health messaging should encourage reducing the consumption of omega 6 FAs and maintaining a healthy balance between omega 3 and omega 6 FAs, rather than focusing on omega-3 FA supplementation. This is because dietary omega-3 supplementation alone is unlikely to help reduce systemic inflammation or inflammation-related disease. **Keywords:** Systemic Inflammation; C-reactive Protein, Glycoprotein Acetyls, Interleukin 6, Polyunsaturated fatty acids, Omega-3; Omega-6; Mendelian Randomization, ALSPAC.

1. Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Non-communicable diseases (NCDs) are the main cause of global mortality, representing 71% of deaths worldwide<sup>2</sup>. As such, their prevention remains a key challenge. Systemic lowgrade inflammation, reflected by elevated concentrations of markers of inflammation such as cytokines (e.g. interleukin-6 (IL-6)) and acute phase proteins (e.g. C-reactive protein (CRP)), has been implicated in the pathophysiology of many NCDs from cardiovascular disease to depression<sup>3-12</sup>. Therefore, inflammation appears a promising target for their treatment and prevention. Polyunsaturated fatty acids (PUFAs), are proposed to influence levels of systemic inflammation<sup>13</sup>. There are two main families of PUFAs which are essential for many metabolic processes: Omega-3 (n-3)<sup>14, 15</sup>; and Omega-6 (n-6)<sup>15</sup>, along with eicosatetraenoic acid and docosahexaenoic (DHA) acid (both n-3 PUFAs), and arachidonic acid (ARA; an n-6 PUFA) linked most clearly to various essential physiological processes. These processes include maintaining cell membrane structural integrity, hormone synthesis, regulation of gene expression, and supporting brain and nervous system functioning 16. Some PUFAs such as ARA can come from both exogenous sources (such as meat and egg products) and endogenous sources. This is where the PUFAs can be synthesized from their metabolomic precursors: α-linolic acid (ALA; an n-3 PUFA) and linolic acid (LA: an n-6 PUFA), through desaturation and elongation reactions <sup>17</sup>. In comparison, humans cannot synthesise LA or ALA and therefore they must be acquired through dietary consumption 18 such as vegetable oils (for LA) and seed oils (ALA).

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

There is some evidence that N-3 PUFAs have anti-inflammatory effects and protect against the severity/occurrence of inflammation-related conditions 19, 20. For example, there are suggestions that fatty fish consumption can reduce the probability of death from a heart attack <sup>21, 22</sup>. This is attributed to n-3 PUFAs ability to alter the production of prostaglandins. which subsequently reduce inflammation (measured by the reduced concentration of circulating inflammatory biomarkers in the blood)<sup>23-26</sup>. However, clinical trials investigating the effects of n-3 supplementation have yielded contradictory results <sup>27 28</sup> regarding its effect on systemic inflammation. Dietary supplementation studies have reported that the consumption of n-6 PUFAs, which are typically thought to be pro-inflammatory, did not affect the concentration of inflammatory markers such as IL-6 or CRP <sup>23, 29-31</sup>. A meta-analysis of 14 clinical trials that included total 1,35,291 participants found that omega-3 supplementation reduced the risk of major adverse cardiovascular event, cardiovascular death and myocardial infarction <sup>32</sup>. In contrast, an RCT study investigating dietary intake and mortality in 3114 men with angina, found that risk of cardiac death was higher among individuals advised to eat oily fish or to take fish oil compared to those not advised to do so. Additionally, RCTs investigating supplementation in patients to treat other inflammation-related NCDs found similarly inconsistent results (e.g. 33 34). However, these studies did not directly test the effect of fatty acids on inflammation levels and the inconsistent findings of the RCTs cast doubt on the posited immune modulatory effect sof n-3 and n-6. Further, the contradictory results also raise questions of whether PUFAs causally influence concentrations of biomarkers of inflammation or whether the observed associations are the result of residual confounding.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Both n-3 and n-6 PUFAs are metabolized by the same enzymes and compete for desaturation and elongation. This means it is plausible that n-6 PUFAs act as competitive inhibitors of n-3 PUFAs and thus reduce the amount of end-product n-3 PUFAs that can be synthesised<sup>35</sup>. As a result, a lower concentration of n-3 PUFAs could reduce their antiinflammatory effects<sup>36-38</sup>. In contrast, a lower plasma n-6:n-3 ratio may result in higher levels of end-product n-3 PUFAs which would subsequently lower concentrations of inflammatory markers leading to beneficial effects on health outcomes<sup>39</sup>. As such, further research to understand the importance of the n-6:n-3 ratio on levels of inflammation and its impact on the occurrence of NCDs is of public health concern. We examined whether circulating levels of PUFAs are associated with systemic biomarkers of inflammation using (1) data from a population-based prospective birth cohort and (2) two-sample Mendelian randomization (MR), a causal inference method that uses genetic variants as proxies to examine whether the association between a risk factor and a disease outcome is likely to be causal or result of residual confounding or reverse causaltion<sup>40</sup>. We investigated the effects on inflammatory markers of specific n-3 and n-6 PUFAs which play a role in key metabolic processes. These are the long-chain n-3 PUFA DHA and the short-chain n-6 PUFA LA which appear at opposite ends of the biosynthesis pathways (see figure 1; adapted from Videla et al. 1). In addition, for a greater interrogation of the PUFAinflammation relationship, we used measures of total n-3 PUFAs, total n-6 PUFAs and the ratio of total n-6 PUFAs:total n-3 PUFAs (referred hereafter as the total n-6:n-3 ratio) as exposures. As outcomes we used three biomarkers for systemic inflammation, namely CRP, IL-6, and Glycoprotein Acetyls or GlycA (a novel composite biomarker of inflammatory acute phase proteins<sup>41, 42</sup>).

2. Results

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

2.1 Findings from Population-based Cohort Analyses Table 1 presents the median/range for PUFA levels (DHA, LA, total n-3 PUFAs and total n-6 PUFAs) and inflammatory biomarker levels (IL-6, CRP and GlycA) from participants of the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort at age 24y. There was no difference between the complete-case and imputed results (eTable 15) and distributions of observed and imputed characteristics are presented in supplementary eTable 16. The results of the below associations are presented in eTable17 and eTable 18. 2.1.1 Associations of DHA and LA with inflammatory markers Both DHA and LA were associated with higher CRP and GlycA levels, but lower IL-6 levels at 24y after adjusting for potential confounders relating to sex, substance use, social economic position, and maternal pregnancy health (Figure 2). 2.1.2 Associations of total n-3 and n-6 PUFAs with inflammatory markers Total n-3 and n-6 PUFAs were associated with higher GlycA levels, but lower IL-6 levels at 24y after adjusting for potential confounders. Total n-6 was associated with higher CRP levels but there was no strong evidence of association between total n-3 PUFAs and CRP (Figure 2). 2.1.3 Associations between total n-6:n-3 ratio and inflammatory markers The total n-6:n-3 ratio was associated with higher levels of all three inflammatory markers (CRP, GlycA and IL-6) at age 24y after adjusting for potential confounders (Figure 2). 2.1.4 Sex Specific Associations between PUFAs and Inflammatory Markers

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

In sex-stratified analyses, the n-6:n-3 ratio was associated with higher levels of all three inflammatory markers in both sexes (Figure 3). PUFAs were also associated with higher GlycA in males and females. The effects of all PUFAs on CRP and IL-6 levels attenuated to the null in males. In females, PUFAs were associated with higher CRP but lower IL-6 levels, which mirrored findings from the whole cohort analysis. 2.2 Results for Mendelian Randomization Analyses We used two-sample MR to assess evidence for causality using publicly available summarylevel data from European population GWAS of the PUFAs<sup>43</sup>, GlycA<sup>44</sup>, CRP<sup>45</sup> and IL-6<sup>46</sup>. See eMethods for further information. Tests investigating instrument validity, described in the methods section, indicated that instruments were unlikely to be subject to weak instrument bias (see eResults). 2.2.1. Potential causal effect of DHA on inflammatory markers We observed no strong evidence of effect of DHA levels on CRP (IVW estimate: 0.03; 95% CI: -0.01, 0.09), GlycA (IVW estimate: 0.01; 95% CI: -0.06, 0.07) or IL-6 (IVW estimate: 0.07; 95% CI: -0.20, 0.07). These results were largely consistent across sensitivity analyses using MR methods that make different assumptions about instrument validity (MR-egger, weighted median and weighted mode) (Figure 4). 2.2.2. Potential causal effect of LA on inflammatory markers We observed no strong evidence of effect of LA levels on CRP (IVW estimate: -0.10; -0.10, 0.09) or IL-6 (IVW estimate: 0.02; -0.05, 0.08). We observed estimates suggesting that higher LA levels cause higher GlycA levels (IVW estimate: 0.25; 0.15, 0.35). Other than in the analysis investigating the effect of LA levels on CRP, results were consistent across MR sensitivity methods (Figure 4).

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

2.2.3. Potential causal effect of total n-3 PUFA levels on inflammatory markers Higher total n-3 PUFA levels were associated with higher CRP (IVW estimate: 0.09; 0.03, 0.16) and GlycA (IVW estimate: 0.12; 0.04, 0.21) levels. We observed no effect of total n-3 PUFA levels on IL-6 (IVW estimate: -0.04; -0.09, 0.02). Results attenuated to the null in all MR sensitivity analyses of total n-3 PUFA levels and GlycA (Figure 4). 2.2.4. Potential causal effect of total n-6 PUFA levels on inflammatory markers We observed no strong evidence of effect of total n-6 PUFA levels on CRP (IVW estimate: 0.04, -0.05, 0.13) or IL-6 (IVW estimate: -0.08; -0.03, 0.04). We did observe estimates that suggest that higher n-6 PUFA levels cause higher GlycA levels (IVW estimate: 0.25; 0.16, 0.34) with estimates consistent in sensitivity analyses with the exception of the weighted mode analysis (Figure 4). 2.3 Evidence of pleiotropy and heterogeneity MR Egger intercepts and tests for heterogeneity between the SNP effect estimates are presented in eTable 19. There was no strong evidence of pleiotropic effect as detected by the MR-Egger intercept for the association between PUFA levels and any biomarker with the exception of the association between total n-3 levels and GlycA. Findings were fairly consistent with results using the MR-PRESSO test for pleiotropy (eTable 20). There was strong evidence of heterogeneity in all analyses apart from in analyses of total n-3 and LA levels and IL-6. 2.4 Findings on the potential impact of methodological biases in MR results MR-Lap <sup>47</sup>was used to assess potential biases in observed effect estimates due to sample overlap between the fatty acid, CRP and GlycA GWAS. Results suggested that the majority of

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

analyses were largely unaffected by winner's curse and weak instrument biases introduced through sample overlap. The corrected effect differed from the observed effect only for analysis investigating the effect of total n-6 PUFAs on GlycA and CRP levels. In both instances, the observed effect estimate was in the same direction as the corrected estimate and the confidence intervals did not cross the null but were wider. See eResults for further information. 2.5 Results from MR Analysis Focusing on Specific Genes The FADS gene cluster and ELOVL2 gene encode key desaturase and elongase enzymes respectively and are involved in the n-3 and n-6 fatty acid biosynthesis pathways. Therefore, we conducted a complementary and mechanistically informative MR analysis by using only genetic instruments from within or close to the FADS gene cluster (FADS1, FADS2 and FADS3) and ELOVL2 gene with the aim of reducing the impact of other pleiotropic pathways. MR analyses using SNPs from the FADS gene region showed that DHA increases CRP levels (IVW estimate: =0.04; 95% CI=0.01, 0.07), but LA decreases CRP levels (IVW estimate: =-0.14; -0.20, -0.07). FADS instrumented DHA and LA had no effect on GlycA and (where testable) IL-6. There was no evidence of a causal effect of any SNPs from the ELOVL2 gene on GlycA, CRP, or IL-6. See eResults for further information. 2.6 Results from analyses exploring heterogeneity of MR instruments Given that evidence of associations between the PUFAs and GlycA were largely consistent across cohort and MR analyses, we used MR-Clust <sup>48</sup>to investigate whether there were distinct clusters of SNPs effects driving the heterogeneity observed in the MR analysis with

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

GlycA levels as the outcome. In the analysis using genetic instruments for LA, total n-3 PUFAs and total n-6 PUFAs, all clusters were positively associated with GlycA which is consistent with the main results. However, for DHA, there were two SNP clusters showing a positive association with GlycA and one cluster showing a negative association with GlycA levels. This could explain the observed null results between DHA and GlycA found in the main analysis. See eResults, eTable 26, and eFigures 3-6 for further information. We obtained functional annotations of the genomic loci associated for all identified clusters from FUMAGWAS (https://fuma.ctglab.nl) and investigated in which tissues the genes were up- or down-regulated (eFigures 7-10). Overall, most differentially expressed genes were expressed in the liver. For the association between DHA and GlycA, tissues with most differentially expressed genes were: liver (cluster 1), breast (cluster 2) and kidneys (cluster 5). For the association between LA and GlycA, tissues with most differentially expressed genes were: liver (clusters 1 and 2) and kidneys (cluster 4). For the association between total omega-3 and GlycA, most differentially expressed genes in both clusters 2 and 6 were in liver. Finally, for the association between total omega-6 and GlycA, most differentially expressed genes were in kidneys (cluster 1) and liver (cluster 4). 2.7 Multivariable MR investigating the direct effects of total omega-3 and total omega-6 on inflammatory markers We conducted a Multivariable Mendelian Randomization (MVMR) analysis to estimate the individual direct causal effects of total n-3 and n-6 PUFAs on the biomarkers of inflammation independently of each other. We observed a positive direct effect of total n-6 PUFA levels on both GlycA (IVW estimate: 0.33; 0.19, 0.47) and CRP levels (IVW estimate: 0.20; 0.01,

0.39), but not IL-6 levels (IVW estimate: 0.17; -0.17, 0.50), after controlling for the effect of n-3 PUFAs. There was no direct effect of total n-3 PUFA levels on GlycA (IVW estimate: 0.06; -0.05, 0.16), CRP (IVW estimate: 0.03; -0.06, 0.12) or IL-6 (IVW estimate: -0.18; -0.49, 0.14) levels after controlling for the effect of n-6 PUFAs. This suggests that the effect of total n-3 PUFAs on CRP levels found in the univariable MR analysis are not independent of the effect of n-6, and may be a result of pleiotropy (Figure 5). See eResults for further information on MVMR analysis.

## 3. Discussion

By combining complementary cohort and genetic analyses, we provide greater insight into the relationships between dietary PUFAs and systemic inflammatory markers. Our analyses of population cohort data show a consistent effect of the n-6:n-3 ratio on higher levels of all three inflammatory markers in the total sample and in males and females separately. However, the picture appears to be more complex when we consider total or individual FA levels. For instance, total n-3 FAs levels which are thought to be anti-inflammatory are not associated with CRP levels. Similarly, n-6 (thought to be pro-inflammatory) as well as n-3 PUFAs are associated with an increase in GlycA levels, but a decrease in IL-6.

Subsequent genetic analyses shed light into the complex nature of these associations including the important issue of causality. First, MR results showing a potentially causal effect of total n-3 PUFAs on higher circulating CRP and GlycA levels contrast the presumed anti-inflammatory effect of n-3 PUFAs, and argues against the widespread use of n-3 supplementation aimed at improving health by reducing inflammation-related disease risk.

Second, our MR results confirm that total n-6 and LA increase GlycA (a pro-inflammatory

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

marker), suggesting a pro-inflammatory effects of these FAs. The importance of n-6 FAs with regards to modulating inflammation, rather than n-3 FAs, was also highlighted by our MVMR analysis which provided evidence for a direct causal effect of total n-6 FAs increasing CRP and GlycA levels after accounting for the effect of total n-3 PUFA levels. In contrast, no independent effect on inflammatory marker levels was observed for total n-3 FAs. Results from our further MR analyses using genetic variants within/nearby a key gene involved in fatty acid metabolism (FADS gene cluster), indicate that several PUFAinflammatory marker associations may result from pleiotropic effects of FA-related genetic variants, rather than the effect of FA biosynthesis. These include the effect of LA on GlycA, effect of total n-3 PUFAs on CRP and GlycA, and effect of total n-6 PUFAs on GlycA. Our approach of investigating the effect of specific genes within the PUFA biosynthesis pathway is similar to recent work by Haycock et al<sup>49</sup> who investigated the effect of FAD1 and FAD2 genes on cancer. They reported that genetically elevated PUFA desaturase activity, instrumented by one SNP (rs174546), was associated with higher risk of colorectal and lung cancer. Future research should investigate whether desaturase activity promotes certain cancer risk through increased inflammation. N-3 and n-6 PUFAs act as competitive inhibitors disrupting each other's desaturation and elongation<sup>36</sup>. Therefore, a greater concentration of n-6 PUFAs would result in a fewer number of endpoint n-3 PUFAs being synthesized. This could be one explanation for the lack of an anti-inflammatory effect of n-3 PUFAs in our work. This may also explain our finding of positive associations between total n-6:n-3 PUFA levels and all three inflammatory marker levels in our cohort analysis.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

A higher n-6:n-3 ratio is thought to promote the pathogenesis of inflammation-related NCDs such as cardiovascular disease, arthritis and asthma<sup>50</sup>, and a meta-analysis of RCTs found that supplementation of a low n-6:n-3 PUFA ratio inducing diet decreased concentrations of inflammatory markers such as tumor necrosis factor- $\alpha$  and IL-6<sup>51</sup>. Therefore, it is possible that n-6:n-3 PUFAs ratio is more important than concentrations of individual PUFAs with regards to the risk of inflammation-related NCDs. We were unable to conduct MR for n6:n3 ratio because of the lack of GWAS for this measure. This should be prioritized when such data becomes available in future. We investigated the association between PUFAs and levels of CRP, IL-6 and GlycA, using two different methods and used sensitivity analyses to address potential biases that arise in epidemiological research. Despite this, we recognize several limitations. We used crosssectional analyses which means it is difficult to infer causality and we cannot determine the temporal relationship between the exposure and the outcome or the directionality of this relationship. Additionally, the cohort analysis was limited to only participants reported as White and the GWAS used were only conducted in individuals of European descent. This limits the generalizability of the results to other populations. However, the cohort analysis provides useful context and provides evidence for associations between PUFA levels and biomarkers of inflammation, including GlycA, which is novel. DHA and LA appear at the different ends of FA biosynthesis pathways (n-3 DHA is an endogenous product of a chain of desaturation and elongation reactions, while LA is a precursor to these reactions on the n-6 PUFA pathway). This means that a comparison between the effects of these specific n-3 and n-6 PUFAs is difficult. Future large-scale, well-powered

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

GWAS of specific PUFAs across the biosynthesis pathway at comparable stages are needed to help better understand this relationship. There was sample overlap between the exposure and outcome GWAS data used for MR analyses, which may lead to overfitting. However, recent research suggests that the bias incurred through sample overlap is less substantial compared to biases produced by weak instruments or winner's curse<sup>47</sup>. These biases are unlikely to be issues for our MR analyses as confirmed by various sensitivity analyses exploring these concerns specifically. Heterogeneity in the two-sample MR analyses may have biased causal estimates towards the null. Although we did investigate the outcome of the heterogeneity within the GlycA analyses using MR-Clust, no clusters were specifically related to inflammation-related processes. Lastly, although the FADS gene cluster encodes enzymes fundamental to PUFA biosynthesis suggesting that IVs within this region are more likely to satisfy MR assumptions, FADS variants have been shown to be highly pleiotropic<sup>52</sup> and do not differentiate n-3 or n-6 effects. As such, our gene based analyses may capture pathways to inflammation through factors other than PUFAs, thus violating the exclusion-restriction assumption<sup>40</sup>. Given the popular use of n-3 PUFAs as supplements to reduce the occurrence of inflammation-related NCDs<sup>27, 53, 54</sup>, our results are of public health importance. Importantly, our MR results suggest that n-6 PUFAs increase levels of CRP and GlycA when controlling for n-3 PUFAs and that a higher total n-6:n-3 ratio increases levels of all three biomarkers. As such, instead of focusing solely on n-3 PUFA consumption, public health messaging should move towards encouraging a lower total n-6 PUFA consumption and to achieve a healthy balance between n-3 and n-6 to help reduce the occurrence of inflammation-related NCDs.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

However, as there is evidence that suggests that n-3 PUFA consumption is also beneficial to health because of its hypotriglyceridaemic effects<sup>55</sup>, a better understanding of the interplay between n-6 and n-3 effects, as well as potential beneficial non-inflammation related effects, is needed before considering implementing n-6 focussed changes to policy. 4. Conclusion Our MR results suggest that higher LA and total n-6 PUFA levels increase GlycA, but not CRP or IL-6 levels. Our MR results also suggest that higher total n-3 PUFA levels increase CRP and GlycA levels, but do not increase IL-6 levels. We provide consistent evidence for positive associations between total n-6:n-3 ratio and levels of CRP, GlycA and IL-6, indicating that the ratio of total n-6:n-3 PUFAs may be more important with regards to systemic inflammation than individuals PUFAs. However, these results came from cross-sectional analyses of cohort data and we were unable to examine evidence of causality for the effects of total n-6:n-3 ratio using MR due to lack of GWAS data for total n-6:n-3 ratio. Nevertheless, our findings do not support a strong anti-inflammatory effect of n-3 PUFAs from both cohort and MR analyses. This finding requires further investigation given that n-3 PUFA supplementation widely used to reduce inflammation and risk of inflammation-related NCDs. 5. Methods 5.1 Cohort Analysis 5.1.1 Dataset and sample The Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort recruited pregnant women resident in Avon, UK with expected dates of delivery between 1st April 1991 and 31<sup>st</sup> December 1992 <sup>56-58</sup>. There were 14, 203 unique mothers initially enrolled in the study and the initial number of pregnancies enrolled was 14,541 and 13,988 children

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

were alive at 1 year of age. When the oldest children were approximately 7 years of age, the initial sample was bolstered with eligible cases who did not originally join the study. The total sample size for analyses using any data collected after the age of seven is therefore, 14,833 unique mothers and 15,447 pregnancies which resulted in 15,658 foetuses. Of these, 14,901 were alive at 1 year of age. The offspring, their mothers and the mother's partners are regularly followed up. Additional information on ALSPAC is presented in the supplement eMethods. For eligibility criteria see the study flowchart (eFigure 1) in the supplement. For this study, ALSPAC participants were included if they had outcome (CRP, IL-6 and GlycA levels) and exposure (DHA, LA, total n-3 and total n-6) data at 24y. We excluded non-white participants (2% of study population) and this exclusion is unlikely to make any difference to the results due to low numbers of non-white individuals in the dataset. This gave a total of 2748 individuals (36.10% males) eligible for our analysis. 5.1.2 PUFAs and inflammatory marker assays Participants fasted overnight, or >6 hours if being seen in the afternoon, before attending the clinic for blood sampling at 24 years old. Blood samples were centrifuged immediately to isolate plasma and stored at -80 °C. There were no freeze-thaw cycles during storage. Total n-3, n-6, DHA and LA PUFA levels and plasma GlycA levels were measured using a highthroughput proton (1H) Nuclear Magnetic Resonance (NMR) metabolomics platform (Nightingale, UK)<sup>42, 59</sup>. We also created a n-6:n-3 ratio (total n-6 PUFAs divided by total n-3 PUFAs). HsCRP was measured by automated particle-enhanced immunoturbidimetric assay (Roche UK, UK). IL-6 was measured by enzyme-linked immunosorbent assay (OLINK, UK). The samples were collected when the participansts were 24 years old. Full dtails regarding sample processing, NMR analysis, and data processing have been provided elsewhere 60-62.

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

GlycA levels ranged from 0.84 to 2.25 mmol/L, and IL-6 levels ranged from 1.82 to 10.60 Normalized Protein expression (NPX) Log2 scale. CRP had detection limits of 0.15-80mg/L and measures outside this were removed. CRP levels ranged from 0.15 to 70.05 mg/L. 5.1.3 Assessment of Covariates We used maternal self-reported highest educational qualification and highest occupation of either parent (measures of social economic position (SEP)), maternal and paternal smoking pattern during pregnancy (measures of pregnancy health), participants' sex, and participants' smoking status and drinking status at age 24 as covariates. A detailed description of how these variables were collected/coded is provided in the supplement eMethods. 5.1.4 Statistical analysis Multivariable linear regression analyses were used to examine the cross-sectional associations of PUFA levels with GlycA ,CRP and IL-6 levels at age 24y. Regression models were adjusted for potential confounders. CRP and IL-6 levels were not normally distributed and were log-transformed. To help with the interpretation of results, we z-transformed both exposure and outcome data, and so the effect estimates represent the increase in outcome in standard deviation (SD) per SD increase in exposure. Primary analyses used the whole sample, and in secondary analyses we stratified by sex. We used multiple imputation (MI) to impute missing exposure, outcome and covariate data in the eligible sample (N=2748), described in detail in the supplement eMethods. 5.2 Two-sample Mendelian Randomisation Analysis 5.2.1 Study design and data sources

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

Genome-wide significant single nucleotide polymorphisms (SNPs) (P< 5.0 x10-8) were selected as IVs for MR analyses. The SNPs were harmonized, aligning the genetic association for exposure and outcome on the effect allele using the effect allele frequency (see eMethods for details). Following harmonisation of the PUFA SNP instrument with the corresponding outcome data (inflammatory biomarker), palindromic SNPs were removed and the remaining SNPs underwent LD clumping. Steiger filtering was then applied, meaning SNPs were removed if they explained more variance in the outcome than in the exposure. The number of SNPs removed due to being palindromic, in linkage disequilibrium (LD) or as a result of Steiger filtering for each analysis is reported in eTable 1. There were 46-58 SNPs available to investigate the effect of PUFAs on GlycA levels, 17-39 SNPs available to investigate the effect of PUFAs on CRP levels and 11-44 SNPs available to investigate the effect of PUFAs on IL-6 levels. Harmonized SNP information for each relationship are presented in eTables 2-13. See eMethods for further details on instrument selection. 5.2.2 Statistical analysis For MR, the inverse variance weighted (IVW)<sup>63</sup> method was used as a primary analysis to calculate effect estimates. MR-Egger, weighted median, and weighted mode methods were used as sensitivity analyses as these methods make different assumptions about instrument validity. Findings were considered robust if results were consistent across primary and sensitivity analyses. We report F-statistics for IVs, as a measure of instrument strength. Presence of heterogeneity between the SNP effect estimates was assessed using Cochran's Q test in the IVW analysis and the Rucker's Q test in the MR-Egger analyses. We used the MR-Egger intercept and MR Pleiotropy Residual Sum and Outlier global test (MR-PRESSO) to

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

investigate the presence of pleiotropy. See eTable 14 for a description of MR methods and sensitivity analyses used<sup>64</sup>. 5.2.3 MR-Lap analysis to investigate bias from sample overlap, weak instrument and Winner's Curse The fatty acid GWAS, the CRP GWAS and GlycA GWAS were conducted using UKB data. This sample overlap may modify biases caused by the use of weak instruments and winner's curse. To overcome this, the MR-Lap method was used to assess potential bias in observed effect estimates due to sample overlap, winner's curse, or weak instruments<sup>47</sup>. Greater detail of MR-Lap method is provided in eMethods. 5.2.4 Additional MR analysis focusing on specific PUFA genes MR was conducted using genetic instruments (SNPs) from within or close to (+/-500 kb) the FADS gene cluster (FADS1, FADS2 and FADS3; chromosome 11: 6125602452-6126592523) and ELOVL2 gene (chromosome 6: 10@980@992-11@044@624) from the DHA GWAS and the LA GWAS. SNPs were selected and harmonised using the same method as in the primary analysis and details are presented in the eMethods. The number of SNPs available for each analysis is presented in eMethods. 5.2.5 MR-Clust analysis to explore heterogeneity in MR instruments SNPs can influence the outcome in distinct ways (e.g., via distinct biological mechanisms)<sup>48</sup>. This can lead to high levels of heterogeneity between individual SNP-outcome/SNPexposure causal estimates within an instrument. Therefore, we decided to use MR-Clust 48 to investigate whether individual causal estimates fell into distinct clusters based on effect magnitude. We used this method when evidence of association was consistent between

cohort and MR analyses but there was strong evidence of heterogeneity in the latter. Functional annotations of the genomic loci associated with identified clusters was obtained from FUMAGWAS (<a href="https://fuma.ctglab.nl">https://fuma.ctglab.nl</a>). See further details in eMethods. 5.2.6 Multivariable Mendelian Randomisation analysis MVMR<sup>65</sup> is an extension of MR that estimates the *direct effect* of each exposure on the outcome, rather than the overall total effect of the exposures (eFigure 2 of the supplement). We conducted a MVMR analysis to estimate the individual direct causal effects of total n-3 and n-6 PUFAs on the biomarkers of inflammation independently of each other. See further details in eMethods. 5.3 Software Cohort analyses were performed using STATA version 17.0. All other analyses were performed in R Software version 4.1.0.

## References

458

- 459 1. Videla LA, Hernandez-Rodas MC, Metherel AH, Valenzuela R. Influence of the nutritional
- status and oxidative stress in the desaturation and elongation of n-3 and n-6 polyunsaturated fatty
- 461 acids: Impact on non-alcoholic fatty liver disease. Prostaglandins, Leukotrienes and Essential Fatty
- 462 Acids 2022; **181**: 102441.
- 463 2. Collaborators GRF. Global burden of 87 risk factors in 204 countries and territories, 1990-
- 464 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223-49.
- 465 3. Calder PC, Albers R, Antoine JM, et al. Inflammatory Disease Processes and Interactions with
- 466 Nutrition. British Journal of Nutrition 2009; 101: 1-45.
- 467 4. Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Seminars in
- 468 Immunopathology; 2009: Springer; 2009. p. 79-94.
- 469 5. Calabro P, Golia E, TH Yeh E. Role of C-reactive protein in acute myocardial infarction and
- 470 stroke: possible therapeutic approaches. Current Pharmaceutical Biotechnology 2012; 13: 4-16.
- 471 6. Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation
- with cancer development, tumor progression and therapy resistance. *Carcinogenesis* 2021; **42**: 1411-473 9.
- 474 7. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk
- 475 of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet
- 476 2012; **379**: 1591-601.
- 8. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin
- on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.
- 479 The Lancet 2011; **377**: 31-41.
- 480 9. Connelly MA, Otvos JD, Shalaurova I, Playford MP, Mehta NN. GlycA, a novel biomarker of
- systemic inflammation and cardiovascular disease risk. *Journal of Translational Medicine* 2017; **15**:
- 482 219.
- 483 10. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major
- 484 depression. *Biol Psychiatry* 2010; **67**: 446-57.
- 485 11. Fries GR, Walss-Bass C, Bauer ME, Teixeira AL. Revisiting inflammation in bipolar disorder.
- 486 Pharmacology Biochemistry and Behavior 2019; 177: 12-9.
- 487 12. Oliveira J, Oliveira-Maia A, Tamouza R, Brown A, Leboyer M. Infectious and immunogenetic
- 488 factors in bipolar disorder. Acta Psychiatrica Scandinavica 2017; 136: 409-23.
- 489 13. Currenti W, Godos J, Alanazi AM, et al. Dietary Fats and Cardio-Metabolic Outcomes in a
- 490 Cohort of Italian Adults. Nutrients 2022; 14: 4294.
- 491 14. El-Badry AM, Graf R, Clavien PA. Omega 3 Omega 6: What is right for the liver? *J Hepatol*
- 492 2007; **47**: 718-25.
- 493 15. Miles EA, Childs CE, Calder PC. Long-Chain Polyunsaturated Fatty Acids (LCPUFAs) and the
- 494 Developing Immune System: A Narrative Review. *Nutrients* 2021; **13**.
- 495 16. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. *Nutr Rev*
- 496 2004; **62**: 333-9.
- 497 17. Sokoła-Wysoczańska E, Wysoczański T, Wagner J, et al. Polyunsaturated Fatty Acids and
- 498 Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. *Nutrients* 2018; 10.
- 499 18. Burns-Whitmore B, Froyen E, Heskey C, Parker T, San Pablo G. Alpha-Linolenic and Linoleic
- 500 Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special
- 501 Consideration? Nutrients 2019; 11.
- 502 19. Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ. Consumption of oily fish and
- 503 childhood asthma risk. Medical Journal of Australia 1996; 164: 137-40.
- 504 20. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J
- 505 Clin Nutr 2006; 83: 1505s-19s.
- 506 21. Chaddha A, Eagle KA. Omega-3 fatty acids and heart health. Circulation 2015; 132: e350-e2.

- 507 22. Kris-Etherton PM, Fleming JA. Emerging nutrition science on fatty acids and cardiovascular
- disease: nutritionists' perspectives. *Adv Nutr* 2015; **6**: 326s-37s.
- 509 23. Pischon T, Hankinson SE, Hotamisligil GKS, Rifai N, Willett WC, Rimm EB. Habitual Dietary
- 510 Intake of n-3 and n-6 Fatty Acids in Relation to Inflammatory Markers Among US Men and Women.
- 511 *Circulation* 2003; **108**: 155-60.
- 512 24. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to
- 513 plasma biomarkers of inflammation and endothelial dysfunction. The Journal of Nutrition 2005; 135:
- 514 562-6.
- 515 25. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation
- 516 lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain, Behavior,
- 517 and Immunity 2011; **25**: 1725-34.
- 518 26. Hu FB, Manson JE. Omega-3 Fatty Acids and Secondary Prevention of Cardiovascular
- Disease—Is It Just a Fish Tale?: Comment on "Efficacy of Omega-3 Fatty Acid Supplements
- 520 (Eicosapentaenoic Acid and Docosahexaenoic Acid) in the Secondary Prevention of Cardiovascular
- 521 Disease". Archives of Internal Medicine 2012; **172**: 694-6.
- 522 27. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated
- fatty acid supplementation for inflammatory joint pain. Pain 2007; 129: 210-23.
- 524 28. MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and
- 525 glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease,
- 526 rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis: Summary.
- 527 AHRQ Evidence Report Summaries. Rockville (MD): Agency for Healthcare Research and Quality (US);
- 528 2004.
- 529 29. Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Arachidonic acid supplementation enhances
- 530 synthesis of eicosanoids without suppressing immune functions in young healthy men. *Lipids* 1998;
- 531 **33**: 125-30.
- 532 30. Thies F, Miles EA, Nebe-von-Caron G, et al. Influence of dietary supplementation with long-
- 533 chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions
- and on plasma soluble adhesion molecules in healthy adults. *Lipids* 2001; **36**: 1183-93.
- 535 31. Kakutani S, Ishikura Y, Tateishi N, et al. Supplementation of arachidonic acid-enriched oil
- 536 increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites
- and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study. *Lipids*
- 538 in Health and Disease 2011; **10**: 1-12.
- 539 32. Shen S, Gong C, Jin K, Zhou L, Xiao Y, Ma L. Omega-3 Fatty Acid Supplementation and
- 540 Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials. Front Nutr
- 541 2022; **9**: 809311.
- 542 33. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized,
- 543 placebo-controlled trial of flax oil in pediatric bipolar disorder. *Bipolar Disorders* 2010; **12**: 142-54.
- 544 34. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in
- mania and bipolar depression. J Clin Psychiatry 2012; 73: 81-6.
- 546 35. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and
- disease. Nature Reviews Neuroscience 2014; 15: 771-85.
- 548 36. Spiller GA. Handbook of Lipids in Human Nutrition. Boca Raton (FL): CRC press; 1995.
- 37. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of
- 550 inflammation: a systematic review and meta-analysis. Food Funct 2021; 12: 30-40.
- 551 38. Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins, Leukotrienes and
- 552 Essential Fatty Acids 2018; **132**: 41-8.
- 553 39. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids
- to circulating inflammatory markers. The Journal of Clinical Endocrinology & Metabolism 2006; 91:
- 555 439-46.
- 556 40. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. Nature Reviews
- 557 Methods Primers 2022; 2: 1-21.

- 558 41. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative
- 559 Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic
- Technologies. *American journal of epidemiology* 2017; **186**: 1084-96.
- 561 42. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic
- 562 resonance metabolomics in cardiovascular epidemiology and genetics. Circulation: cardiovascular
- 563 genetics 2015; 8: 192-206.
- 564 43. Borges MC, Haycock PC, Zheng J, et al. Role of circulating polyunsaturated fatty acids on
- 565 cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic
- association data from over 114,000 UK Biobank participants. BMC Medicine 2022; 20.
- 567 44. Clayton GL, Borges MC, Lawlor DA. From menarche to menopause: the impact of
- reproductive factors on the metabolic profile of over 65,000 women. medRxiv 2022:
- 569 https://doi.org/10.1101/2022.04.17.22273947
- 570 45. Ligthart S, Vaez A, Võsa U, et al. Genome analyses of> 200,000 individuals identify 58 loci for
- 571 chronic inflammation and highlight pathways that link inflammation and complex disorders. The
- 572 *American Journal of Human Genetics* 2018; **103**: 691-706.
- 573 46. Ahluwalia TS, Prins BP, Abdollahi M, et al. Genome-wide association study of circulating
- interleukin 6 levels identifies novel loci. *Hum Mol Genet* 2021; **30**: 393-409.
- 575 47. Mounier N. Bias correction for inverse variance weighting Mendelian randomization. Genetic
- 576 *Epidemiology* 2023; **47**: 314-31.
- 577 48. Foley CN, Mason AM, Kirk PDW, Burgess S. MR-Clust: clustering of genetic variants in
- 578 Mendelian randomization with similar causal estimates. Bioinformatics 2020; 37: 531-41.
- 579 49. Haycock PC, Borges MC, Burrows K, et al. The association between genetically elevated
- 580 polyunsaturated fatty acids and risk of cancer. EBioMedicine 2023; 91: 104510.
- 581 50. Simopoulos AP, Cleland LGCE. Omega-6/omega-3 essential fatty acid ratio: The Scientific
- 582 Evidence. Scandinavian Journal of Nutrition 2004; **48**: 49-50.
- 583 51. Wei Y, Meng Y, Li N, Wang Q, Chen L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of
- 584 inflammation: a systematic review and meta-analysis. Food & Function 2021; 12: 30-40.
- 585 52. Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome
- 586 prioritizes metabolites implicated in human diseases. *Nature Genetics* 2023; **55**: 44-53.
- 587 53. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll
- 588 Nutr 2002; **21**: 495-505.
- 589 54. Bouzan C, Cohen JT, Connor WE, et al. A quantitative analysis of fish consumption and stroke
- 590 risk. Am J Prev Med 2005; 29: 347-52.
- 591 55. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated
- fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Adv Food Nutr Res 2012; 65: 211-22.
- 593 56. Boyd A, Golding J, Macleod J, et al. Cohort Profile: the 'children of the 90s'--the index
- offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 2013; 42: 111-27.
- 595 57. Fraser A, Macdonald-Wallis C, Tilling K, et al. Cohort Profile: the Avon Longitudinal Study of
- 596 Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 2013; 42: 97-110.
- 597 58. Northstone K, Lewcock M, Groom A, et al. The Avon Longitudinal Study of Parents and
- 598 Children (ALSPAC): an update on the enrolled sample of index children in 2019. Wellcome Open Res
- 599 2019; **4**: 51.
- 59. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-
- effective holistic studies on systemic metabolism. *Analyst* 2009; **134**: 1781-5.
- 602 60. Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum NMR metabonomics for cost-
- effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5.
- 604 61. Inouye M, Kettunen J, Soininen P, et al. Metabonomic, transcriptomic, and genomic variation
- of a population cohort. Mol Syst Biol 2010; 6: 441.
- 606 62. Goulding N, Goudswaard L, Hughes D, et al. Inflammation proteomics datasets in the ALSPAC
- cohort [version 1; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Research
- 608 2022; **7**.

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638 639

640

641

642

643

644

645

646

647

63. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in Medicine 2008; **27**: 1133-63. Crick D, Sanderson E, Jones H, et al. Glycoprotein Acetyls and Depression: testing for directionality and potential causality using longitudinal data and Mendelian randomization analyses. medRxiv; 2022. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. International Journal of Epidemiology 2019; 48: 713-27. **Acknowledgements** This work was carried out using the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. Contributions Daisy C.P. Crick: Conceptualization, Methodology, Investigation, Writing - original draft, Writing - review & editing. Hannah Jones: Writing - Conceptualization, Supervision, Methodology, review & editing. Sarah Halligan: Supervision, Writing – review & editing. Golam M. Khandaker: Conceptualizaion, Methodology, Supervision, Writing – review & editing. George Davey Smith: Methodology, Writing - review & editing. Correspondence to Daisy Crick Competing interests Authors declare no relevant potential conflict of interest related to the material presented in the article. Data availability Data needed to evaluate the conclusions presented in this paper are provided in the manuscript and/or the supplementary material. Additionally ALSPAC data can be requested from the ALSPAC executive committee and reasonable requests from bona fide researchers. GWAS data is publicly available using the OpenGWAS website (https://gwas.mrcieu.ac.uk)

648 Code availability 649 Code for data management and statistical analysis has been made available in daisycrick 650 (github.com). 651 652 653 Funding 654 The UK Medical Research Council and Wellcome (Grant ref.: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the 655 656 authors and DC will serve as guarantor for the contents of this paper. A comprehensive list 657 of grants funding is available on the ALSPAC website 658 (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This 659 research was specifically funded by Wellcome Trust and MRC (core) (Grant ref.: 76467/Z/05/Z), MRC (Grant ref.: MR/L022206/1) and Wellcome Trust (Grant 660 661 ref.: 8426812/Z/07/Z). 662 This work was supported in part by the GW4 BIOMED DTP (D.C., MR/N0137941/), awarded 663 to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council 664 (MRC)/UKRI. 665 GDS, GMK and HJ work within the MRC Integrative Epidemiology Unit at the University of 666 Bristol, which is supported by the Medical Research Council (MC UU 00011/1). 667 GMK acknowledges funding support from the Wellcome Trust (grant no: 201486/Z/16/Z and 668 201486/B/16/Z), the UK Medical Research Council (grant no: MC UU 00032/06; 669 MR/W014416/1; and MR/S037675/1), and the UK National Institute of Health Research 670 Bristol Biomedical Research Centre (grant no: NIHR 203315). HJ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and 671 672 Weston NHS Foundation Trust and the University of Bristol. The views expressed are those 673 of the author(s) and not necessarily those of the NIHR or the Department of Health and 674 Social Care. 675 676 677 678 679 680 681 682 683 684

Tables

Table 1: Median and interquartile range of exposure and outcome data (n = 2748)

	Median (IQR)	Range
GlycA (mmol/L)	1.22 (1.12-1.34)	0.84-2.25
CRP (mmol/l)	0.87 (0.39-2.29)	0.1-70.05
IL-6 (NPX log2)	3.32 (2.96-3.85)	1.82-9.86
DHA	0.11 (0.09-0.13)	0.04-0.32
LA	2.31 (1.98-2.68)	0.89-4.91
Total n-3 PUFAs	0.29 (0.24-0.34)	0.07-0.80
Total n-6 PUFAs	2.85 (2.48-3.28)	1.23-5.82




Figure 1: Schematic representation of polyunsaturated fatty acid biosynthesis in mammals adapted from Videla 2022  $^{\,1}$ 




Figure 2: Association between fatty acids and inflammatory biomarkers using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic




Figure 3: Association between fatty acids and inflammatory biomarkers stratified by sex using cohort data after adjusting estimates for household social class, maternal highest education qualification, maternal and paternal smoking status during pregnancy, offspring sex and age and status at 24 year clinic




Figure 4: Univariable causal effect of fatty acids on Inflammation




Figure 5: Multivariable Mendelian randomization analysis of direct effect of Omega-3 and Omega-6 on Inflammation